Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth &...
Transcript of Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth &...
![Page 1: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/1.jpg)
Kyung Hae Jung Asan Medical Center
Seoul, Korea
![Page 2: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/2.jpg)
Medical insurance system in Korea
Current evidence and real management
for breast cancer patients in Korea
![Page 3: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/3.jpg)
Only one provider, Government
(National Health Insurance Corporation)
All people have mandatorily joined the
medical insurance policy since 1989
![Page 4: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/4.jpg)
Public
institution
Private
institution
93%
Is meant for all the hospital or
organization for medical treatment not to
reject application of medical insurance
but to offer an appropriate medical care
to the patients.
![Page 5: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/5.jpg)
OECD Health Data 2012
‘2012
OECD 9.3%
Korea 7.5%
‘2002
OECD 8.0%
Korea 4.8%
![Page 6: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/6.jpg)
‘2012
OECD 6.7%
Korea 4.2%
OECD Health Data 2012
Korea
OECD av.
‘2002
OECD 5.7%
Korea 2.6%
![Page 7: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/7.jpg)
Health & Welfare Policy Forum 2013;196:89-102
![Page 8: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/8.jpg)
OECD Health Data 2011
![Page 9: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/9.jpg)
![Page 10: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/10.jpg)
Level of evidence : Category 1
No drug for replacement or substitution
No increase in financial burden for
provider
![Page 11: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/11.jpg)
But, cancer patients pay only 5% of all
medical cost if covered by insurance
Usually they are provided with good
quality cancer care with low economic
burden.
![Page 12: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/12.jpg)
4.9
9.7
10.8
15.7
18.6
22.5
20.8
20.0
21
.1
25.6
19.4
21.2
19.8
18.9
24.3
23.1
22.9
27.0
23.9
25
.4
23.6
27.2
25.8
24.5
28.8
24.6
27.0
30.6
29.4
30.5
31.5
33
.4
6.1
10.8
11.4
13.4
16.4
17
.4
17.7
18.1
18.5
18.6
19.1
19.1
19.3
19.7
19.7
19.8
19.8
19.9
20.3
21.0
21.4
21.6
22.1
22.3
23.2
23.6
24.1
24.7
25.0
25.6
26.1
28.6
0
5
10
15
20
25
30
35
2000 2009Age-standardised rates per 100 00 females
OECD Health Care Quality Indicators
OECD 22.9% 19.8%
Korea 4.9% 6.1%
![Page 13: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/13.jpg)
Korea Central Cancer Registry, 2010
Thyroid Stomach
Colon Lung
Liver Prostate Biliary
Pancreas NHL
Breast
![Page 14: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/14.jpg)
Trial N ORR TTP/PFS
(months)
OS
(months)
von Minckwitz et al. (2009)
Capecitabine
Capecitabine+Trastuzumab
156
27%
48.1%
TTP
5.6
8.2
P=0.03
20.4
25.5
P=0.26
Geyer et al. (2006)
Capecitabine
Capecitabine+Lapatinib
324
14%
22%
P=0.009
TTP
4.4
8.4
P<0.001
Blackwell et al (2010)
Lapatinib
Lapatinib+Trastuzumab
296
6.9
10.3
P=0.46
8.4 wks
12 wks
P=0.008
39 wks
51.6 wks
P=0.016
![Page 15: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/15.jpg)
Beyond progression during or within 1
year of adjuvant trastuzumab, physicians
have to change to lapatinib/capecitabine in
HER2-positive metastatic breast cancer.
And then, no anti-HER2 targeted agents
are allowed anymore.
![Page 16: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/16.jpg)
Anderson M et al. JCO 2011;29:264-271
HERNATA study:1st line
Trastuzumab/Docetaxel vs.
Trastuzumab/Vinorelbine
![Page 17: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/17.jpg)
Anderson M et al. JCO 2011;29:264-271
HERNATA study:1st line
Trastuzumab/Docetaxel vs.
Trastuzumab/Vinorelbine
More Gr ¾ toxicities in Docetaxel arm :
Febrile neutropenia (36.0% vs 10.1%)
Leucopenia (40.3% vs 21.0%)
Infecttion (25.1% vs 13.0%)
Fever (4.3% vs 0%)
Neruopathy (7.9% vs 0.7%)
Edema (6.5% vs 0%)
![Page 18: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/18.jpg)
Trastuzumab combined with taxane is the
only one regimen allowed to use and
reimburssed.
Other combinations in current NCCN
guideline, such as trastuzumab with
vinorelbine, capecitabine, or lapatinib
should not be used.
![Page 19: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/19.jpg)
Pertuzumab (Perjeta)
Activates antibody-dependent cellular cytotoxicity
Inhibits HER2-mediated signalling
Inhibits shedding and, thus, formation of new p95
Inhibits HER2-related angiogenesis
Hubbard 2005
Trastuzumab
Pertuzumab
Activates antibody-dependent
cellular cytotoxicity
Prevents receptor dimerization
Potent inhibitor of HER2/HER2-
and HER2/HER3-mediated
signalling pathways
![Page 20: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/20.jpg)
Baselga et al. N Engl J Med 2012;366:109-
19.
![Page 21: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/21.jpg)
At 30 months median follow up
Baselga et al. N Engl J Med 2012;366:109-19.
![Page 22: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/22.jpg)
![Page 23: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/23.jpg)
Monoclonal antibody: trastuzumab
Target expression: HER2
Highly potent chemotherapy
(maytansine derivative)
Cytotoxic agent: DM1
Systemically stable Breaks down in target cancer cell
Linker T-DM1
(Kadcyla®
)
![Page 24: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/24.jpg)
Verma et al, N Engl J Med
2012;367:1783-91
![Page 25: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/25.jpg)
ORR : Cape/Lap : 31%, T-DM1 : 44%, p<0.002
Verma et al, N Engl J Med 2012;367:1783-91
![Page 26: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/26.jpg)
Verma et al, N Engl J Med 2012;367:1783-91
![Page 27: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/27.jpg)
Wildiers H, SB Kim et al, ECCO 2013
![Page 28: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/28.jpg)
![Page 29: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/29.jpg)
![Page 30: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/30.jpg)
![Page 31: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/31.jpg)
New anti-HER2 targeted agents,
pertuzumab and T-DM1, are not available
now.
Outlook of their reimbursement in the near
future is very dim.
![Page 32: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/32.jpg)
Lancet 2011; 377: 914–23
PFS OS
13.2 vs 10.5m 3.7 vs 2.2m
![Page 33: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/33.jpg)
2012 SABCS
![Page 34: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/34.jpg)
New drugs for patients with HER2-
negative cancer are very expensive and
not reimbursed, yet.
Eribulin ca 4,000 USD/cycle
Everolimus/Exemestane ca 2,700 USD/month
Less than 5% of patients indicated are
treated with these drugs.
![Page 35: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/35.jpg)
aHormone receptor-positive patients receive adjuvant tamoxifen; AP, doxorubicin 60 mg/m2, paclitaxel 150 mg/m2; H, Herceptin® 8 mg/kg loading then 6 mg/kg; LABC, locally advanced breast cancer; P, paclitaxel 175 mg/m2; q3w, every 3 weeks; q4w, every 4 weeks
HER2-positive LABC
(IHC 3+ and / or FISH+)
n=118
H + AP
q3w x 3
H + P
q3w x 4
H q3w x 4
+ CMF q4w x 3
Surgery followed by
radiotherapya
H continued q3w
to Week 52
P
q3w x 4
CMF
q4w x 3
Surgery followed by
radiotherapya
n=117
AP
q3w x 3
AP
q3w x 3
P
q3w x 4
CMF
q4w x 3
Surgery followed by
radiotherapya
n=99
HER2-negative LABC
(IHC 0/1+)
19(16%) patients crossed to
H after November 2005
![Page 36: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/36.jpg)
![Page 37: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/37.jpg)
Gianni, et al. Lancet 2010;375:377
![Page 38: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/38.jpg)
Reveals a significant interaction (p=0.037) of
treatment and pCR
EFS benefit from trastuzumab is significantly linked to
pCR, and almost restricted to pCR
pCR with trastuzumab is linked to significant EFS
benefit, while association of pCR and EFS is smaller
and non significant without trastuzumab
![Page 39: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/39.jpg)
![Page 40: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/40.jpg)
The regimen used in NOAH trial is the
only one approved as neoadjuvant
treatment in HER2-positive breast cancer.
But it’s not reimbursed now.
![Page 41: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/41.jpg)
How do patients feel in current
medical environment in Korea?
![Page 42: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/42.jpg)
Health & Welfare Policy Forum 2013;196:89-102
Unm
et needs (%
)
Unm
et needs (%
)
% of out-of-pocket payment % of out-of-pocket payment
![Page 43: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/43.jpg)
Patients and doctors in Korea have many obstacles to access to modern &/or expensive drugs proven to increase clinical outcome and feel uncomfortable.
We need more information on predicting benefits and toxicities of treatment in individual patient.
Consensus and wisdom are eagerly needed for fair distribution of limited medical resources.
![Page 44: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/44.jpg)
Thank you for your attention !
![Page 45: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/45.jpg)
....???
![Page 46: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/46.jpg)
![Page 47: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/47.jpg)
1997-2002 2004-2009
OECD (17) 78.7 83.7
Korea 76.7 82.2
Japan 86.1 87.3
Singapore 68.7 78.5
67.9
68.7
70.8
72.3
79.3
75.0
76.2
76.7
82.7
82.8
74.5
78.7
79.5
77.0
83.1
84.2
82.4
85.6
86.1
88.6
73.0
76.9
78.5
78.6
80.3
81.2
81.3
82.0
82.0
82.2
0.0
83.3
83.7
84.4
84.5
86.0
86.1
86.2
86.3
86.3
86.5
86.6
87.3
89.3
0 20 40 60 80 100 120
Latvia
Slovenia
Singapore
Czech Republic
Ireland
Austria
United Kingdom
Denmark
Portugal
Korea
Malta
France
Germany
OECD (17)
Netherlands
New Zealand
Sweden
Israel
Belgium
Iceland
Finland
Norway
Canada
Japan
United States
Age-standardised rates (%)
2004-2009 1997-2002
![Page 48: Kyung Hae Jung Asan Medical Center Seoul, Koreagbcc.kr/upload/SY03-1_Kyung Hae Jung.pdfHealth & Welfare Policy Forum 2013;196:89-102 . OECD Health Data 2011 Level of evidence : Category](https://reader036.fdocuments.in/reader036/viewer/2022081410/60a047eef60c4a324c6d2d0d/html5/thumbnails/48.jpg)
Ministry of Health & Welfare
Insurance
subscribers
Medical institution
Health Insurance
Review &
Assessment Service
National
Health
Insurance
Corporation